4,919 results on '"Giralt, Sergio"'
Search Results
2. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
3. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma
4. Phase I Trial of MCARH109, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis
5. Transplantation and Cellular Therapy for Older Adults—The MSK Approach
6. Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease
7. Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies
8. Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort
9. Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.
10. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses
11. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
12. Artificial intelligence enabled interpretation of ECG images to predict hematopoietic cell transplantation toxicity
13. Anti-ceramide Single-Chain Variable Fragment Mitigates Gastrointestinal-Acute Radiation Syndrome and Improves Marrow Reconstitution, Rendering Near-Normal 90-Day Autopsies
14. Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma
15. Application of the CIBMTR One Year Survival Outcomes Calculator as a tool for retrospective analysis
16. Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
17. Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies
18. Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)
19. CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
20. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
21. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
22. Optimizing high dose melphalan
23. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing
24. Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
25. Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation
26. Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
27. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant
28. EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation
29. Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy
30. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study.
31. Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma
32. Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation
33. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.
34. Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes
35. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma
36. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis
37. Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia
38. High-resolution analyses of associations between medications, microbiome, and mortality in cancer patients
39. DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma
40. Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation
41. A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract
42. Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study
43. Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: Recommendations from an international expert panel
44. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy
45. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
46. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
47. Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation
48. CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis
49. Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant
50. CD34-selected allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in the tyrosine kinase era
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.